The Board Meeting on Biopharma Boardroom Diversity 2017 London

Event Location: BMA, Tavistock Square, London. WC1H 9JP. - United Kingdom
Event Date: March 28th 2017
Event Schedule:
3.00pm - 3.30pm – Event Registration and Networking
3.30pm – 3.40pm – Welcoming Address
3.40pm – 4.00pm – “Why Diversity” Presentation
4.00pm – 4.30pm – Panel – Surveying the UK’s Diversity Landscape: Policies and Programmes...Action to Embed Lasting Change!
4.30pm – 4.45pm – Expert Presentation to the Board
4.45pm – 5.00pm – Coffee Break
5.00pm – 6.30pm – ‘The Board Meeting’ (main panel)
Under the direction of a Chairperson, a gender balanced board of leading industry executives debated the value of diverse leadership. The board's agenda tackled the most prominent questions in the three following areas:
6.30pm – 7.30pm – Networking Reception and Close
Speakers included:
Dr Annalisa Jenkins - CEO of Dimension Therapeutics and non-executive director of MedCity, Ardelyx, Biothera, and Viventia Bio, Inc.; John Berriman - Chairman at Confo Therapeutics, Depixus, ReNeuron Group, Autifony Therapeutics; Dr Denise Scots-Knight - CEO and Founder at Mereo Biopharma Group, Plc., non-executive director OncoMed and Albireo; Prof. Isabel Fernandez-Mateo - Professor of Strategy and Entrepreneurship, London Business School, Jeanne Bolger - VP Venture Investments, J&J Innovation JJDC Denis Woulfe - Partner and Vice Chairman, Deloitte, Co-Chair MACA and Board Member of Women's Business Council; Gerry Brown, Chairman, Novaquest Capital Management, Pavita Cooper, Steering Committee Member of 30% Club, Chair of CMI Diversity Advisory Group and Founder of More Difference. Roel Bulthuis, SVP and Managing Director, Merck Ventures, Dr Elena Doldor, Assistant Professor in Organizational Behaviour, School of Business and Management Queen Mary University of London and Senior Research Fellow - Cranfield School of Management, Catherine Moukheibir, Chairperson of MedDay Pharma, non-executive director Ablynx, Cerenis and Zealand Pharma; Dr Yvonne Thompson CBE, Entrepreneur, Author and Steering Committee Member of the Parker Review. Dr Stephen Bunting, Chairman, Abingworth LLP., Paul George, Executive Director of Corporate Governance and Reporting, Financial Reporting Council
Featured content
comments powered by Disqus